Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions ...

A recent study found that men with low testosterone levels were associated with a 60 percent higher risk that prostate cancer could progress to a more aggressive state over time. Prostate cancer is ...

Prostate cancer is one of the most common cancers among men. Many cases grow slowly and may never become life-threatening. Because of this, doctors often recommend a management approach called “active ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

John Tesh is continuing to battle cancer ten years after doctors gave him 18 months to live. "I was given 18 months to live," the former TV personality told Page Six. "So, I’ve been fighting cancer ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

No increased risk for thrombosis or bleeding seen with concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs.

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

John Tesh says he has outlived a terminal cancer prognosis by nearly eight years while continuing treatment for metastatic prostate cancer.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and ...